Table 2 General characteristics of included studies (about the relationships between Nestin expression and OS or PFS in glioma patients)
First author | Year | Origin country | No. of patients | Median/mean age (year) | WHO grade | Detect method | Cut off level | Survival end points | Follow up period | Survival analysis | Adjusted variables |
|---|---|---|---|---|---|---|---|---|---|---|---|
Hatanpa [19] | 2014 | USA | 50 | median 37.5 years (20–66) | II–III | IHC | median | OS | 4.3 year | multivariate (KM) | nestin, IDH, WHO grade, oligodendroglioma component (astrocytoma or oligoastrocytoma), MIB-1, age, sex, extent of resection and type of adjuvant, therapy |
Milde [20] | 2012 | Russia | 379 | NR | II–III | IHC | 50 % | OS | median 53 months | multivariate | cytogenetic group only, or cytogenetic group and posterior fossa group |
PFS | |||||||||||
wan [21] | 2011 | Germany | 283 | NR | II–IV | IHC | median | OS | Mean 11.21 ± 4.26 years | multivariate | WHO grade, patient age at diagnosis and extent of resection |
Kim [12] | 2011 | Korea | 88 | mean 54.9 years (13–80) | IV | IHC | 50 % | OS | mean 13.9 (1–53) months | multivariate | age, sex, KPS, extent of removal, chemoradiotherapeutic modality, temozolomide modality, after temozolomide therapy and stem cell marker expression |
PFS | |||||||||||
Arai [22] | 2012 | Japan | 64 | median 55 years (11–79) | III–IV | IHC | 60 % | OS | 1–67 months | KM | NR |
Dahlrot [18] | 2014 | Denmark | 25 | NR | II | IF | median | OS | Media 12 months | multivariate | age, performance status (PS) and IDH1 status |
PFS | |||||||||||
Dahlrot [18] | 2014 | Denmark | 26 | NR | III | IF | median | OS | Media 12 months | multivariate | age, performance status (PS) and IDH1 status |
PFS | |||||||||||
Dahlrot [18] | 2014 | Denmark | 185 | NR | IV | IF | median | OS | Media 12 months | multivariate | age, performance status (PS) and IDH1 status |